Valeant ready to raise Allergan bid to at least $200/share: Reuters
Valeant Pharmaceuticals International Inc on Monday said in a letter to Allergan Inc's board of directors that it was prepared to raise its offer to at least US$200 per share but stopped short of doing so, Reuters reported. At US$200 per share, the offer would be worth more than US$59 billion. Canada's Valeant and hedge fund Pershing Square Capital Management launched a hostile offer for Allergan in April, but the U.S.-based Botox maker has staunchly refused it.
27 October 2014•3 mins read
